PURPOSE PD 0313052 is a potent, direct factor Xa (FXa) inhibitor (Ki = 0.33 nM) and its antithrombotic effect has been previously demonstrated in several animal models, via intravenous (IV) administration. In the present study, we evaluated four different subcutaneous (SC) formulations to test the feasibility of developing PD 0313052 as a subcutaneous agent. METHODS PD 0313052 was formulated ...

BACKGROUND Most conventional methods for delivering chemotherapeutic agents fail to achieve therapeutic concentrations of drugs, despite reaching toxic systemic levels. Novel controlled drug delivery systems are designed to deliver drugs at predetermined rates for predefined periods at the target organ and overcome the shortcomings of conventional drug formulations therefore could diminish the ...

Carvedilol (CAR) is a potent antihypertensive drug but has poor oral bioavailability (24%). A nanosuspension suitable for pulmonary delivery to enhance bioavailability and bypass first-pass metabolism of CAR could be advantageous. Accordingly, the aim of this work was to prepare CAR nanosuspensions and to use artificial neural networks associated with genetic algorithm to model and optimize the...

Methane hydrates were studied in systems containing aqueous dissolved surfactants oil emulsions with a volume ratio of 40/60. Two commercial surfactants, named synperonic PE/F127 and cetyltrimethylammonium bromide, evaluated at 0, 350, 700 1500 ppm. Experiments made by applying the cooling–heating path an isochoric high-pressure cell different initial pressures 5.5, 8.0, 10.0 12.0 MPa. The obta...

Mesoporous  MgO  microstructures  were  synthesized  using magnesium  acetate  tetrahydrate,  ammonium  oxalate  monohydrate and  Pluronic  F127  via  heating  at  40  °C  for  24  h  and  subsequent calcination. The mesoporous structure of magnesium oxide with the specific  surface  area  of  47m2 /g,  pore  volume  0.30  cm3 /g  and  the average pore size 24 nm is produced. According to ...